Lung Cancer

Breathe easy and try Proteintech’s unparalleled antibodies and ready-to-use IHC kits to further accelerate your lung cancer research

---

Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using MCM6 polyclonal antibody (13347-2-AP), the #1 cited antibody on the market. MCM6 plays a crucial role in lung cancer metastasis.

Introduction

Lung cancer is the second most common cancer worldwide and by far the leading cause of cancer-related deaths. There are two major forms of lung cancer. Non-small cell lung cancer (NSCLC) accounts for most cases and can be divided into several different types including adenocarcinoma, squamous cell, and large cell carcinoma. Small cell lung cancers account for about 10-15% of lung cancer cases but are more invasive and faster growing than NSCLC. While smoking remains the number one cause of lung cancer, exposure to toxic chemicals as well as inherited and acquired genetic mutations can also contribute towards developing this disease. Proteintech offers several antibodies and IHC kits to study disease progression and to identify existing and potential biomarkers for targeted therapies. Many of these products have already been validated in lung cancer tissue.

Featured Markers for Lung Cancer Research

KRAS

KRAS is an oncogenic protein that has the second highest rate of mutation in NSCLC behind p53. It is a member of the RAS family of proteins that coordinate several cellular activities including proliferation, survival, and cytoskeletal remodeling. KRAS mutations are often corelated with poor survival and response to treatment. Proteintech’s KRAS antibody is one of the most cited in the market, already featured in nearly 100 publications worldwide.

Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using 12063-1-AP (KRAS antibody) at dilution of 1:800 (under 10x lens).

MET

MET is a receptor tyrosine kinase that is activated upon binding with its ligand, HGF. Ligand binding activates several downstream cellular responses including cell growth, adhesion, and motility. In lung cancer, this protein is often overexpressed or affected by gain-of-function mutations. These alterations result in dysregulated signaling and increased cancer invasiveness. Several inhibitory drugs and monoclonal antibodies have been developed to target aberrant MET activity in lung cancer.  

Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using 25869-1-AP (c-Met antibody) at dilution of 1:1000 (under 10x lens).

STK11

STK11, also known as LKB1, is a protein kinase that controls the activity of members of the AMP-activated protein kinase (AMPK) family. It is normally a tumor suppressor that functions as an upstream regulator of cell polarization, apoptosis, and the DNA damage response. However, STK11 is affected by loss of function mutations in nearly 13% of lung adenocarcinomas, which result in oncogenic functions. Lung cancers carrying mutated forms of STK11 tend to have a higher propensity for metastasis and lower overall survival.

Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using 10746-1-AP (STK11/LKB1 antibody) at dilution of 1:200 (under 10x lens).

Antibodies for Lung Cancer

Function	Marker	PTG Catalog
Angiogenesis	COX2	12375-1-AP
Cell Cycle and Proliferation	ALK	24184-1-AP
	BRAF	20899-1-AP
	CDK4	11026-1-AP
	EGFR	18986-1-AP
	HER2	18299-1-AP
	KI67	27309-1-AP
	KRAS	12063-1-AP
	MCM7	11225-1-AP
	P53	10442-1-AP
	PTEN	22034-1-AP
	RACK1	27952-1-AP
	STK11	10746-1-AP
	TP63	12143-1-AP
Cancer Type Differentiation	Chromogranin A	10529-1-AP
	CD56	14255-1-AP
	GRP	28482-1-AP
	Napsin A	16558-1-AP
	NSE	10149-1-AP
	P40	15105-1-AP
	SCCA	26558-1-AP
	SOX2	11064-1-AP
	Synaptophysin	17785-1-AP
	Vimentin	10366-1-AP
Metastasis	ALDOA	11217-1-AP
	Cathepsin D	21327-1-AP
	Clusterin	12289-1-AP
	E cadherin	20874-1-AP
	HJURP	15283-1-AP
	MCM6	13347-2-AP
	MET	25869-1-AP
	MUC1	23614-1-AP
	NCL	10556-1-AP
Survival	AKT	10176-2-AP
	GLUT1	21829-1-AP
	HDAC6	12834-1-AP
	HGF	26881-1-AP
	HSP90	13171-1-AP
	PD-L1	66248-1-Ig

IHC Kits for Lung Cancer 

Function	Marker	PTG Catalog
Angiogenesis	COX2	KHC0770
Cell Cycle and Proliferation	CDK4	KHC0303
	EGFR	KHC0612
	P53	KHC0079
	PTEN	KHC0280
	STK11	KHC0278
	TP63	KHC0086
Cancer Type Differentiation	Chromogranin A	KHC0602
	CD56	KHC0734
	Napsin A	KHC0068
	SOX2	KHC0294
	Synaptophysin	KHC0059
	Vimentin	KHC0039
Metastasis	ALDOA	KHC0488
	Cathepsin D	KHC0374
	E cadherin	KHC0010
	MUC1	KHC0304
Survival	AKT	KHC0115
	GLUT1	KHC0036
	HDAC6	KHC0616
	HGF	KHC0478
	HSP90	KHC0659

References

Greulich, H. (2010). The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies. Genes & Cancer, 1(12), 1200–1210. https://doi.org/10.1177/1947601911407324

Laderian, B., Mundi, P. S., Fojo, T., & Bates, S. E. (2020). Emerging Therapeutic Implications of STK11 Mutation: Case Series. Oncologist, 25(9), 733–737. https://doi.org/10.1634/theoncologist.2019-0846

Lawrence, R. E., & Salgia, R. (2009). MET molecular mechanisms and therapies in lung cancer. Cell Adhesion & Migration, 4(1), 146–152. https://doi.org/10.4161/cam.4.1.10973

Sumbly, V., & Landry, I. (2022). Unraveling the Role of STK11/LKB1 in Non-small Cell Lung Cancer. Cureus. https://doi.org/10.7759/cureus.21078

Villalobos, P., & Wistuba, I. I. (2017). Lung Cancer Biomarkers. Hematology-Oncology Clinics of North America, 31(1), 13–29. https://doi.org/10.1016/j.hoc.2016.08.006

What Is Lung Cancer? | Types of Lung Cancer. (n.d.). https://www.cancer.org/cancer/lung-cancer/about/what-is.html